953 related articles for article (PubMed ID: 9488310)
1. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M.
Schrell UM; Koch HU; Marschalek R; Schrauzer T; Anders M; Adams E; Fahlbusch R
J Neurosurg; 1998 Mar; 88(3):541-8. PubMed ID: 9488310
[TBL] [Abstract][Full Text] [Related]
2. Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor.
Wang Y; Robledo O; Kinzie E; Blanchard F; Richards C; Miyajima A; Baumann H
J Biol Chem; 2000 Aug; 275(33):25273-85. PubMed ID: 10854424
[TBL] [Abstract][Full Text] [Related]
3. Activation of Jak-Stat and MAPK2 pathways by oncostatin M leads to growth inhibition of human glioma cells.
Halfter H; Friedrich M; Postert C; Ringelstein EB; Stögbauer F
Mol Cell Biol Res Commun; 1999 May; 1(2):109-16. PubMed ID: 10356359
[TBL] [Abstract][Full Text] [Related]
4. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130.
Hermanns HM; Radtke S; Haan C; Schmitz-Van de Leur H; Tavernier J; Heinrich PC; Behrmann I
J Immunol; 1999 Dec; 163(12):6651-8. PubMed ID: 10586060
[TBL] [Abstract][Full Text] [Related]
5. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells.
Klausen P; Pedersen L; Jurlander J; Baumann H
Oncogene; 2000 Jul; 19(32):3675-83. PubMed ID: 10951574
[TBL] [Abstract][Full Text] [Related]
6. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
J Clin Invest; 1995 Sep; 96(3):1319-27. PubMed ID: 7657807
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein.
Chevalier S; Fourcin M; Robledo O; Wijdenes J; Pouplard-Barthelaix A; Gascan H
J Biol Chem; 1996 Jun; 271(25):14764-72. PubMed ID: 8662918
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of IL-6-type cytokine-induced STAT activation by PMA.
Terstegen L; Maassen BG; Radtke S; Behrmann I; Schaper F; Heinrich PC; Graeve L; Gatsios P
FEBS Lett; 2000 Jul; 478(1-2):100-4. PubMed ID: 10922477
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of oncostatin M and leukaemia inhibitory factor expression in astrocytoma cells.
Kasza A; Rogowski K; Kilarski W; Sobota R; Bernas T; Dobrucki J; Travis J; Koj A; Bugno M; Kordula T
Biochem J; 2001 Apr; 355(Pt 2):307-14. PubMed ID: 11284716
[TBL] [Abstract][Full Text] [Related]
10. Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells.
Halfter H; Postert C; Friedrich M; Ringelstein EB; Stögbauer F
Brain Res Mol Brain Res; 2000 Sep; 80(2):198-206. PubMed ID: 11038252
[TBL] [Abstract][Full Text] [Related]
11. Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6.
Kuropatwinski KK; De Imus C; Gearing D; Baumann H; Mosley B
J Biol Chem; 1997 Jun; 272(24):15135-44. PubMed ID: 9182534
[TBL] [Abstract][Full Text] [Related]
12. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
[TBL] [Abstract][Full Text] [Related]
13. Oncostatin M and leukemia inhibitory factor regulate the growth of normal human breast epithelial cells.
Grant SL; Douglas AM; Goss GA; Begley CG
Growth Factors; 2001; 19(3):153-62. PubMed ID: 11811789
[TBL] [Abstract][Full Text] [Related]
14. Signaling of type II oncostatin M receptor.
Auguste P; Guillet C; Fourcin M; Olivier C; Veziers J; Pouplard-Barthelaix A; Gascan H
J Biol Chem; 1997 Jun; 272(25):15760-4. PubMed ID: 9188471
[TBL] [Abstract][Full Text] [Related]
15. Soluble glycoprotein 130 (gp130) attenuates OSM- and LIF-induced cartilage proteoglycan catabolism.
Hui W; Bell M; Carroll G
Cytokine; 2000 Feb; 12(2):151-5. PubMed ID: 10671300
[TBL] [Abstract][Full Text] [Related]
16. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor.
Gearing DP; Comeau MR; Friend DJ; Gimpel SD; Thut CJ; McGourty J; Brasher KK; King JA; Gillis S; Mosley B
Science; 1992 Mar; 255(5050):1434-7. PubMed ID: 1542794
[TBL] [Abstract][Full Text] [Related]
17. Induction of differentiation by IL-6-type cytokines is impaired in myeloid leukaemia cells unable to activate Stat5a.
Piekorz RP; Hocke GM
Cytokine; 1997 Sep; 9(9):639-49. PubMed ID: 9325012
[TBL] [Abstract][Full Text] [Related]
18. Oncostatin M: a new potent inhibitor of iodine metabolism inhibits thyroid peroxidase gene expression but not DNA synthesis in porcine thyroid cells in culture.
Isozaki O; Tsushima T; Miyakawa M; Emoto N; Demura H; Arai M; Sato-Nozoe Y
Thyroid; 1997 Feb; 7(1):71-7. PubMed ID: 9086575
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown.
Rowan AD; Koshy PJ; Shingleton WD; Degnan BA; Heath JK; Vernallis AB; Spaull JR; Life PF; Hudson K; Cawston TE
Arthritis Rheum; 2001 Jul; 44(7):1620-32. PubMed ID: 11465713
[TBL] [Abstract][Full Text] [Related]
20. Are LIF and related cytokines functionally equivalent?
Piquet-Pellorce C; Grey L; Mereau A; Heath JK
Exp Cell Res; 1994 Aug; 213(2):340-7. PubMed ID: 8050491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
